{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:42:40Z","timestamp":1791909760264,"version":"4.3.4"},"reference-count":80,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Histoplasmosis causes life-threatening disseminated infection in adult patients living with untreated HIV. Although disease incidence has declined dramatically in countries with access to antiretroviral therapy, histoplasmosis remains prevalent in many resource-limited regions. A high index of suspicion for histoplasmosis should be maintained in the setting of a febrile multisystem illness in severely immunosuppressed patients, particularly in persons with hemophagocytic lymphohistiocytosis. Preferred treatment regimens for initial therapy include liposomal amphotericin B for severe disease, or itraconazole for mild to moderate disease. Subsequently, itraconazole maintenance therapy should be administered for at least one year and then discontinued if CD4 count increases to \u2265150 cells\/\u00b5L. Antiretroviral therapy, which improves outcome when administered together with an antifungal agent, should be instituted immediately, as the risk of triggering Immune Reconstitution Syndrome is low. The major risk factor for relapsed infection is nonadherence. Itraconazole prophylaxis reduces risk for histoplasmosis in patients with CD4 counts &lt;100\/\u00b5L but is not associated with survival benefit and is primarily reserved for use in outbreaks. Although most patients with histoplasmosis have not had recognized high-risk exposures, avoidance of contact with bird or bat guano or inhalation of aerosolized soil in endemic regions may reduce risk. Adherence to effective antiretroviral therapy is the most important strategy for reducing the incidence of life-threatening histoplasmosis.<\/jats:p>","DOI":"10.3390\/jof7060429","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T11:33:20Z","timestamp":1622201600000},"page":"429","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment and Prevention of Histoplasmosis in Adults Living with HIV"],"prefix":"10.3390","volume":"7","author":[{"given":"David S.","family":"McKinsey","sequence":"first","affiliation":[{"name":"Metro Infectious Disease Consultants, Kansas City, MO 64132, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3201\/eid1709.101987","article-title":"Geographic distribution of endemic fungal infections among older persons, United States","volume":"17","author":"Baddley","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1089\/apc.1998.12.775","article-title":"Histoplasmosis in the acquired immunodeficiency syndrome: Advances in management","volume":"12","author":"McKinsey","year":"1998","journal-title":"AIDS Patient Care STDs"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00005792-199011000-00004","article-title":"Disseminated histoplasmosis in the acquired immunodeficiency syndrome: Clinical findings, diagnosis and treatment, and review of the literature","volume":"69","author":"Wheat","year":"1990","journal-title":"Medicine"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Nacher, M., Valdes, A., Adenis, A., Blaizot, R., Abboud, P., Demar, M., Djossou, F., Epelboin, L., Misslin, C., and Ntab, B. (2020). Disseminated histoplasmosis in HIV-infected patients: A description of 34 years of clinical and therapeutic practice. J. Fungi, 6.","DOI":"10.3390\/jof6030164"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/hiv.12609","article-title":"Secular trends in opportunistic infections, cancers, and mortality in patients with AIDS during the era of modern combination antiretroviral therapy","volume":"19","author":"Sezgin","year":"2018","journal-title":"HIV Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Couppi\u00e9, P., Herceg, K., Bourne-Watrin, M., Thomas, V., Blanchet, D., Alsibai, K.D., Louvel, D., Djossou, F., Demar, M., and Blaizot, R. (2019). The broad clinical spectrum of disseminated histoplasmosis in HIV-Infected patients: A 30 years\u2019 experience in French Guiana. J. Fungi, 5.","DOI":"10.3390\/jof5040115"},{"key":"ref_7","first-page":"113","article-title":"HIV-associated histoplasmosis: Current perspectives","volume":"12","author":"Myint","year":"2020","journal-title":"HIV AIDS"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1128\/CMR.00027-06","article-title":"Histoplasmosis: A clinical and laboratory update","volume":"20","author":"Kauffman","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2217\/fmb.15.25","article-title":"Histoplasma capsulatum, lung infection and immunity","volume":"10","author":"Horwath","year":"2015","journal-title":"Future Microbiol."},{"key":"ref_10","first-page":"157","article-title":"Histoplasma capsulatum: Mechanisms for pathogenesis","volume":"422","author":"Mittal","year":"2019","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1086\/513653","article-title":"Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: Incidence, risk factors, and pathophysiology","volume":"24","author":"McKinsey","year":"1997","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e13087","DOI":"10.1111\/ctr.13087","article-title":"Histoplasmosis in transplant recipients","volume":"31","author":"Gajurel","year":"2017","journal-title":"Clin. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s12281-008-0015-1","article-title":"Diagnosis and management of histoplasmosis","volume":"2","author":"McKinsey","year":"2008","journal-title":"Curr. Fungal Infect. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00019048-199511000-00030","article-title":"Cluster of histoplasmosis cases in prisoners with HIV Infection","volume":"4","author":"Koletar","year":"1995","journal-title":"Infect. Dis. Clin. Pract."},{"key":"ref_15","first-page":"234","article-title":"Disseminated histoplasmosis in AIDS. Clinicopathologic features in seven patients from a non-endemic area","volume":"90","author":"Ankobiah","year":"1990","journal-title":"N. Y. State J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4049\/jimmunol.177.3.1763","article-title":"B Cells and CD4\u2212CD8\u2212T Cells are key regulators of the severity of reactivation histoplasmosis","volume":"177","author":"Allen","year":"2006","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1034\/j.1399-3062.2002.01016.x","article-title":"Incidence of histoplasmosis following allogeneic bone mar-row transplant or solid organ transplant in a hyperendemic area","volume":"4","author":"Vail","year":"2002","journal-title":"Transpl. Infect. Dis."},{"key":"ref_18","first-page":"7","article-title":"Histoplasmosis in the acquired immunodeficiency syndrome","volume":"7","author":"Wheat","year":"1996","journal-title":"Curr. Top. Med. Mycol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1086\/313824","article-title":"Factors associated with severe manifestations of histoplasmosis in AIDS","volume":"30","author":"Wheat","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nacher, M., Alsibai, K.D., Valdes, A., Blaizot, R., Abboud, P., Demar, M., Djossou, F., Epelboin, L., Misslin, C., and Ntab, B. (2020). Risk Factors for Mortality among HIV-Infected Patients with Disseminated Histoplasmosis. J. Fungi, 6.","DOI":"10.3390\/jof6040326"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"ofv055","DOI":"10.1093\/ofid\/ofv055","article-title":"Histoplasmosis-induced hemophagocytic syndrome: A case series and review of the literature","volume":"2","author":"Townsend","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/7107326","article-title":"Histoplasmosis-associated hemophagocytic lymphohistiocytosis: A review of the literature","volume":"2019","author":"Jabr","year":"2019","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nguyen, D., Nacher, M., Epelboin, L., Melzani, A., Demar, M., Blanchet, D., Blaizot, R., Alsibai, K.D., Abboud, P., and Djossou, F. (2020). Hemophagocytic lymphohistiocytosis during HIV infection in Cayenne Hospital 2012\u20132015: First think histoplasmosis. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.574584"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood.2018894618","article-title":"Recommendations for the management of hemophagocytic lymphohistiocytosis in adults","volume":"133","author":"Horne","year":"2019","journal-title":"Blood"},{"key":"ref_25","first-page":"27","article-title":"Histoplasmosis in Missouri: Historical review and current clinical concepts","volume":"91","author":"McKinsey","year":"1994","journal-title":"Mo. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1055\/s-0031-1295721","article-title":"Pulmonary histoplasmosis","volume":"32","author":"McKinsey","year":"2011","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/infdis\/jiw085","article-title":"Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000\u20132010","volume":"214","author":"Buchacz","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/313843","article-title":"Epidemiology of Human Immunodeficiency Virus\u2013associated opportunistic infections in the United States in the era of highly active antiretroviral therapy","volume":"30","author":"Kaplan","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00042560-200206010-00003","article-title":"Predictive value of HIV-1 viral load on risk for opportunistic infection","volume":"30","author":"Swindells","year":"2002","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Benedict, K., McCracken, S., Signs, K., Ireland, M., Amburgey, V., Serrano, J.A., Christophe, N., Gibbons-Burgener, S., Hallyburton, S., and Warren, K.A. (2020). Enhanced surveillance for histoplasmosis\u20149 states, 2018\u20132019. Open Forum Infect. Dis., 7.","DOI":"10.1093\/ofid\/ofaa343"},{"key":"ref_31","unstructured":"Centers for Disease Control and Prevention (2021, May 03). Estimated HIV Incidence and Prevalence in the United States, 2010\u20132015. HIV Surveillance Supplemental Report. 2018 23 (No. 1), Available online: http:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/1545109710378167","article-title":"HIV-associated histoplasmosis in a nonendemic area of the United States during the HAART era: Role of migration from endemic areas and lack of antiretroviral therapy","volume":"9","author":"Anderson","year":"2010","journal-title":"J. Int. Physicians AIDS Care"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Adenis, A., Nacher, M., Hanf, M., Vantilcke, V., Boukhari, R., Blachet, D., Demar, M., Aznar, C., Carme, B., and Couppi\u00e9, P. (2014). HIV-associated histoplasmosis early mortality and incidence trends: From neglect to priority. PLoS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0003100"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Falci, D.R., Monteiro, A.A., Caurio, C.F.B., Magalh\u00e3es, T.C.O., Xavier, M.O., Basso, R.P., Melo, M., Schwarzbold, A.V., Ferreira, P.R.A., and Vidal, J.E. (2019). Histoplasmosis, an underdiagnosed disease affecting people living with HIV\/AIDS in Brazil: Results of a multicenter prospective cohort Study using both classical mycology tests and Histoplasma urine antigen detection. Open Forum Infect. Dis., 6.","DOI":"10.1093\/ofid\/ofz073"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"655","DOI":"10.7326\/0003-4819-111-8-655","article-title":"Long-term amphotericin B therapy for disseminated histo-plasmosis in patients with acquired immunodeficiency syndrome (AIDS)","volume":"111","author":"McKinsey","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7326\/0003-4819-118-8-199304150-00006","article-title":"Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome","volume":"118","author":"Wheat","year":"1993","journal-title":"Ann. Intern. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0002-9343(99)80311-8","article-title":"Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome","volume":"98","author":"Wheat","year":"1995","journal-title":"Am. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0002-9343(97)00151-4","article-title":"Treatment of Histoplasmosis with Fluconazole in Patients With Acquired Immunodeficiency Syndrome","volume":"103","author":"Wheat","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-137-2-200207160-00008","article-title":"Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS","volume":"137","author":"Johnson","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"576","DOI":"10.4269\/ajtmh.2005.73.576","article-title":"Disseminated histoplasmosis: A comparative study between patients with acquired immunodeficiency syndrome and non-human immunodeficiency virus-infected individuals","volume":"73","author":"Agudelo","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_41","first-page":"CD013594","article-title":"Treating progressive disseminated histoplasmosis in people living with HIV","volume":"4","author":"Murray","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/MD.0000000000000016","article-title":"Histoplasmosis in patients with human immunodeficiency virus\/acquired immunodeficiency syndrome (HIV\/AIDS): Multicenter study of outcomes and factors associated with relapse","volume":"93","author":"Myint","year":"2014","journal-title":"Medicine"},{"key":"ref_43","first-page":"45","article-title":"Strategies to improve HIV treatment adherence in developed countries: Clinical management at the individual level","volume":"3","author":"Enriquez","year":"2011","journal-title":"HIV\/AIDS"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and Sporanox capsule formulations in healthy volunteers in fed and fasted states","volume":"59","author":"Abuhelwa","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drug monitoring: Established and emerging indications","volume":"53","author":"Andes","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/521259","article-title":"Management of patients with histoplasmosis: Clinical practice guidelines by the Infectious Diseases Society of America","volume":"45","author":"Wheat","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Thompson, G.R., Lewis, P., Mudge, S., Patterson, T.F., and Burnett, B.P. (2020). Open-label crossover oral bioequivalence pharmacokinetics comparison for a 3-day loading dose regimen and 15-day steady-state administration of SUBA-itraconazole and conventional itraconazole capsules in healthy adults. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.00400-20"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/420749","article-title":"Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy","volume":"38","author":"Goldman","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1128\/AAC.46.1.248-250.2002","article-title":"Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS","volume":"46","author":"Wheat","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1086\/323781","article-title":"Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome","volume":"33","author":"Wheat","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/jac\/dkl133","article-title":"Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole","volume":"57","author":"Wheat","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/mmy\/myx130","article-title":"In vitro activity of isavuconazole against fluconazole-resistant isolates of Histo-plasma capsulatum","volume":"56","author":"Spec","year":"2018","journal-title":"Med. Mycol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Hendrix, M.J., Larson, L., Rauseo, A.M., Rutjanawech, S., Franklin, A.D., Powderly, W.G., and Spec, A. (2020). Voriconazole versus itraconazole for the initial and step-down treatment of histoplasmosis: A retrospective cohort. Clin. Infect. Dis., 1555.","DOI":"10.1093\/cid\/ciaa1555"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1128\/AAC.43.2.322","article-title":"Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice","volume":"43","author":"Connolly","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jinf.2006.05.006","article-title":"Salvage treatment of histoplasmosis with posaconazole","volume":"54","author":"Restrepo","year":"2007","journal-title":"J. Infect."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mmcr.2019.12.013","article-title":"HIV-associated disseminated histoplasmosis successfully treated with isavuconazole consolidation therapy","volume":"27","author":"Mazzella","year":"2020","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_57","unstructured":"(2021, May 27). Clinicalinfo Information on HIV\/AIDS Treatment, Prevention and Research, NIH, Available online: https:\/\/clinicalinfo.hiv.gov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: A new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1128\/AAC.44.7.1850-1854.2000","article-title":"Comparison of the echinocandin caspofungin with amphotericin B for treatment of Histoplasmosis following pulmonary challenge in a murine model","volume":"44","author":"Kohler","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1128\/AAC.01681-10","article-title":"Investigation of the efficacy of micafungin in the treatment of histoplasmosis using two North American strains of Histoplasma capsulatum","volume":"55","author":"Hage","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","unstructured":"Sobel, J.D., Ouellette, M., Kaye, K.S., and Marchaim, D. (2017). Antifungal Therapy for Histoplasmosis: Focus on Susceptibility, Resistance, and Effectiveness in Humans and Experimental Infection, Springer International Publishing."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/21505594.2016.1235653","article-title":"Antifungal therapeutics for dimorphic fungal pathogens","volume":"8","author":"Goughenour","year":"2017","journal-title":"Virulence"},{"key":"ref_63","first-page":"643","article-title":"Incidence and trends in immune reconstitution inflammatory syndrome associated with Histoplasma capsulatum among people living with human immunodeficiency virus: A 20-year case series and literature review","volume":"70","author":"Melzani","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1055\/s-0035-1562899","article-title":"Histoplasmosis: Up-to-date evidence-based approach to diagnosis and management","volume":"36","author":"Hage","year":"2015","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/QAD.0b013e3282f4a607","article-title":"Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: A prospective study","volume":"22","author":"Murdoch","year":"2008","journal-title":"AIDS"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zolopa, A.R., Andersen, J., Komarow, L., Sanne, I., Sanchez, A., Hogg, E., Suckow, C., Powderly, W., and ACTG A5164 Study Team (2009). Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: A multicenter randomized strategy trial. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005575"},{"key":"ref_67","unstructured":"Panel on Opportunistic Infections in Adults and Adolescents with HIV (2021, May 04). Guidelines for the Prevention and Treatment of Op-portunistic Infections in Adults and Adolescents with HIV: Recommendations from the Centers for Disease Control and Pre-vention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America, Available online: http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1164\/rccm.2008-740ST","article-title":"An Official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients","volume":"183","author":"Limper","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_69","unstructured":"(2020). Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV, Pan American Health Organization and World Health Organization. Available online: https:\/\/iris.paho.org."},{"key":"ref_70","first-page":"1003","article-title":"Histoplasmosis-related Healthcare Use, Diagnosis, and Treatment in a Commercially Insured Population, United States","volume":"70","author":"Benedict","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_71","first-page":"1011","article-title":"Histoplasmosis: Time to redraw the map and up our game","volume":"70","author":"McKinsey","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1086\/319756","article-title":"Multicenter case-control study of risk factors for histoplasmosis in Human Immunodeficiency Virus-infected persons","volume":"32","author":"Hajjeh","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Nacher, M., Adenis, A., Blanchet, D., Vantilcke, V., Demar, M., Basurko, C., Gaubert-Mar\u00e9chal, E., Dufour, J., Aznar, C., and Carme, B. (2014). Risk factors for disseminated histoplasmosis in a cohort of HIV-infected patients in French Guiana. PLOS Negl. Trop. Dis., 8.","DOI":"10.1371\/journal.pntd.0002638"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJM199503163321102","article-title":"A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection","volume":"332","author":"Powderly","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1086\/514744","article-title":"Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: Randomized, placebo-controlled, double-blind study","volume":"28","author":"McKinsey","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1128\/AAC.44.6.1585-1587.2000","article-title":"Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection?","volume":"44","author":"Goldman","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Deepe, G.S. (2018). Outbreaks of histoplasmosis: The spores set sail. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007213"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3201\/eid2203.151117","article-title":"Epidemiology of Histoplasmosis Outbreaks, United States, 1938\u20132013","volume":"22","author":"Benedict","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"ref_79","unstructured":"Lenhart, S.W., Schafer, C.M.P., Singal, M., and Hajjeh, R.A. (1997). Histoplasmosis: Protecting Workers at Risk, DHHS (NIOSH). Publication No. 97-146."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s11046-020-00431-2","article-title":"Re-drawing the maps for endemic mycoses","volume":"185","author":"Ashraf","year":"2020","journal-title":"Mycopathologia"}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/7\/6\/429\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:10:03Z","timestamp":1760163003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/7\/6\/429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":80,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jof7060429"],"URL":"https:\/\/doi.org\/10.3390\/jof7060429","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]}}}